Cancer and Metastasis Reviews

, Volume 32, Issue 3, pp 465–477

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation


  • Sara De Dosso
    • Oncology Institute of Southern Switzerland
  • Enrique Grande
    • Ramón y Cajal University Hospital
  • Jorge Barriuso
    • La Paz University Hospital
  • Daniel Castellano
    • Doce de Octubre University Hospital
  • Josep Tabernero
    • Vall d’Hebron University Hospital
    • Vall d’Hebron University Hospital
    • Department of Medical OncologyVall d’Hebron University Hospital

DOI: 10.1007/s10555-013-9421-0

Cite this article as:
De Dosso, S., Grande, E., Barriuso, J. et al. Cancer Metastasis Rev (2013) 32: 465. doi:10.1007/s10555-013-9421-0


The molecular events of tumorigenesis in neuroendocrine tumors are poorly understood. Understanding of the molecular alterations will lead to the identification of molecular markers, providing new targets for therapeutics. The purpose of this review was to critically analyze the genetic abnormalities in neuroendocrine tumors, with the aim of identifying biomarkers that indicate a response to agents developed against these targets and to serve as an understanding for the combinations of different active compounds. Human epidermal growth factor receptor 1/2 (EGFR and HER2), vascular endothelial growth factor receptors, hepatocyte growth factor receptor (c-Met), platelet-derived growth factor receptor, insulin-like growth factor, phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway, and heat shock proteins are all interesting candidate biomarkers with involvement in carcinogenesis and tumor evolution of several neoplasms, including neuroendocrine tumors. Some of them have already been evaluated both as targets and also as biomarkers in clinical trials conducted in advanced neuroendocrine tumor settings, and others should encourage further investigations into innovative therapeutic opportunities.


Neuroendocrine tumorBiomarkerTarget therapyTyrosine kinase inhibitor

Copyright information

© Springer Science+Business Media New York 2013